Imricor Medical Systems (ASX:IMR) said that its second-generation vision-magnetic resonance ablation catheter to be used for the potential treatment of type 1 atrial flutter has received CE mark certification under the European Medical Device Regulation (MDR), according to a Wednesday filing with the Australian bourse.
The certification received after an on-site audit conducted by IMR's notified body in October 2024 allows the catheter to be manufactured under the MDR, the filing said.
Imricor plans to submit the device for approval by the Australian Therapeutic Goods Administration.
Shares of the company rose almost 4% in recent Wednesday trade.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。